European Regulatory Strategy ‘Should Prioritize Real World Evidence’
Innovative Clinical Trials Should Be Priority Too, Says EFPIA.
Executive Summary
EFPIA, the European Federation of Pharmaceutical Industries and Associations, has put forward what it thinks the European regulatory network strategy to 2025 should prioritize.
You may also be interested in...
EU Drug Regulatory Network Faces Up To An Uncertain And Complex Future
Regulators have produced yet another strategy outlining the challenges and next steps for the European drug regulatory network as the network prepares for a future characterized by rapid developments in science and technology, medicines access issues, supply chain weaknesses and emerging health threats.
Focusing On The Bigger Picture At The EMA
In an exclusive interview with the Pink Sheet, the European Medicines Agency’s Tony Humphreys explains the thinking behind the agency’s regulatory science strategy, why the PRIME scheme is to get a boost – and why the need to tackle health threats ranked so low in a stakeholder consultation.
Novo Nordisk Hit With UK Industry Association Suspension Over Weight Loss Drug Promotion
Novo Nordisk has been hit by a serious sanction in the UK after having been found to effectively pay pharmacists to promote Saxenda.